Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02696434 · ClinicalTrials.gov registry record · Phase 3
Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL
A Phase 3 study, sponsored by Alkermes.
- Completed
- Registry status
- Phase 3
- Development phase
- 101
- Enrollment target
NCT02696434 is a Phase 3 study that has completed, run by Alkermes. The registered enrollment target is 101 participants.
The verdict
NCT02696434, a Phase 3 study, has completed, sponsored by Alkermes.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 101 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy, safety, and tolerability of oral naltrexone used in conjunction with buprenorphine in adults with Opioid Use Disorder transitioning from buprenorphine maintenance prior to the first dose of VIVITROL.
Interventions
- DRUG Placebo
- DRUG Buprenorphine
- DRUG Naltrexone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2016-04 |
| Est. Completion | 2017-11-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02696434
The ClinicalTrials.gov registry entry for NCT02696434 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alkermes, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02696434 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02696434 about?
NCT02696434 is a clinical study titled "Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL". This study will evaluate the efficacy, safety, and tolerability of oral naltrexone used in conjunction with buprenorphine in adults with Opioid Use Disorder transitioning from buprenorphine maintenance prior to the first dose of VIVITROL.
What is the current status of trial NCT02696434?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 101 participants. The study started on 2016-04. Estimated completion is 2017-11-30.
What interventions are being tested in trial NCT02696434?
The interventions under investigation include: Placebo (DRUG), Buprenorphine (DRUG), Naltrexone (DRUG).
Who is sponsoring clinical trial NCT02696434?
This trial is sponsored by Alkermes, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.